Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Beneish M-Score: -2.38 (As of Jun. 26, 2026)


FRA:GU5 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
72 GF Score
Price €1.57
GF Value €2.36
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Beneish M-Score?

Guangzhou Baiyunshan Pharmaceutical Holdings Co FRA:GU5 -2.48% 72 Beneish M-Score is -2.38 as of Jun. 26, 2026. GuruFocus rates FRA:GU5 with a GF Score™ of 72/100 and a GF Value™ of €2.36 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 113 Medical Distribution companies, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks worse than 63.72% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.38 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Guangzhou Baiyunshan Pharmaceutical Holdings Co's Beneish M-Score or its related term are showing as below:

FRA:GU5' s Beneish M-Score Range Over the Past 10 Years
Min: -3.34   Med: -2.33   Max: -0.19
Current: -2.38

During the past 13 years, the highest Beneish M-Score of Guangzhou Baiyunshan Pharmaceutical Holdings Co was -0.19. The lowest was -3.34. And the median was -2.33.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Guangzhou Baiyunshan Pharmaceutical Holdings Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Beneish M-Score Chart

Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.26 -2.47 -2.33 -2.43 -2.26

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.33 -2.37 -2.41 -2.26 -2.38

FRA:GU5 vs MCK, COR, CAH: Beneish M-Score Comparison

For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Beneish M-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Guangzhou Baiyunshan Pharmaceutical Holdings Co's Beneish M-Score falls into.


FRA:GU5
72GF Score
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd FRA:GU5
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Guangzhou Baiyunshan Pharmaceutical Holdings Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1082+0.528 * 0.9929+0.404 * 0.8826+0.892 * 1.0001+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1788+4.679 * 0.017722-0.327 * 1.0612
=-2.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €3,393 Mil.
Revenue was 2921.472 + 1946.104 + 2364.747 + 2337.768 = €9,570 Mil.
Gross Profit was 593.392 + 214.109 + 380.579 + 368.693 = €1,557 Mil.
Total Current Assets was €8,166 Mil.
Total Assets was €11,265 Mil.
Property, Plant and Equipment(Net PPE) was €1,059 Mil.
Depreciation, Depletion and Amortization(DDA) was €0 Mil.
Selling, General, & Admin. Expense(SGA) was €386 Mil.
Total Current Liabilities was €5,116 Mil.
Long-Term Debt & Capital Lease Obligation was €656 Mil.
Net Income was 223.872 + -39.642 + 94.955 + 83.897 = €363 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0 Mil.
Cash Flow from Operations was -278.321 + 210.919 + 170.455 + 60.387 = €163 Mil.
Total Receivables was €3,062 Mil.
Revenue was 2867.574 + 2089.887 + 2294.161 + 2317.359 = €9,569 Mil.
Gross Profit was 588.199 + 270.705 + 338.384 + 348.285 = €1,546 Mil.
Total Current Assets was €7,104 Mil.
Total Assets was €10,214 Mil.
Property, Plant and Equipment(Net PPE) was €1,014 Mil.
Depreciation, Depletion and Amortization(DDA) was €0 Mil.
Selling, General, & Admin. Expense(SGA) was €327 Mil.
Total Current Liabilities was €4,607 Mil.
Long-Term Debt & Capital Lease Obligation was €324 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3393.433 / 9570.091) / (3061.815 / 9568.981)
=0.354587 / 0.319973
=1.1082

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1545.573 / 9568.981) / (1556.773 / 9570.091)
=0.161519 / 0.162671
=0.9929

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8166.076 + 1059.002) / 11265.153) / (1 - (7103.797 + 1014.48) / 10213.981)
=0.181096 / 0.20518
=0.8826

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9570.091 / 9568.981
=1.0001

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1014.48)) / (0 / (0 + 1059.002))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(385.757 / 9570.091) / (327.201 / 9568.981)
=0.040309 / 0.034194
=1.1788

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((655.944 + 5116.051) / 11265.153) / ((324.287 + 4607.444) / 10213.981)
=0.512376 / 0.482841
=1.0612

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(363.082 - 0 - 163.44) / 11265.153
=0.017722

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Guangzhou Baiyunshan Pharmaceutical Holdings Co has a M-score of -2.40 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.38 mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Beneish M-Score of -2.38 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #72 out of 113 companies in the Medical Distribution industry, placing it in the top 63.7%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Beneish M-Score too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Beneish M-Score is -2.38. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #72 out of 113 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Beneish M-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #72 out of 113 companies for Beneish M-Score. This places Guangzhou Baiyunshan Pharmaceutical Holdings Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Distribution company?
A good Beneish M-Score depends on the Medical Distribution industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Beneish M-Score is -2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.36, compared to a current price of €1.57 — trading 33.5% below its estimated fair value. The current Beneish M-Score is -2.38. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Beneish M-Score is -2.38 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of €1.57 is trading 33.5% below its estimated GF Value™ of €2.36. GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.

Key valuation signals for FRA:GU5:

  • Beneish M-Score: -2.38
  • GF Value™: €2.36 vs. price of €1.57 (33.5% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description

Other Exchanges 00874:Hong Kong600332:China
Address 45 Sha Mian North Street, Liwan District, Guangdong Province, Guangzhou, CHN, 510130
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
72GF Score

Get the complete analysis for FRA:GU5

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.57
Price
€2.36
GF Value